Carregant...
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of disease-modifying drugs used for MS act on the inflammatory component of the disease and are approved for use in relap...
Guardat en:
| Publicat a: | Neuropsychiatr Dis Treat |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5922247/ https://ncbi.nlm.nih.gov/pubmed/29719400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S147874 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|